Why ImmunityBio, Inc.’s (IBRX) Stock Is Up 6.02%
As of Wednesday, August 19, ImmunityBio, Inc.’s IBRX share price has surged by 6.02%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Commentary & Analysis
Why ImmunityBio, Inc.’s (IBRX) Stock Is Up 5.47%
As of Wednesday, August 05, ImmunityBio, Inc.’s IBRX share price has surged by 5.47%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About ImmunityBio, Inc.'s Q3 Earnings
ImmunityBio, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (IBRX) missed or beat analyst's expectations.Jenna Brashear
Why ImmunityBio, Inc.’s (IBRX) Stock Is Down 5.24%
As of Tuesday, August 04, ImmunityBio, Inc.’s IBRX share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ImmunityBio, Inc.’s (IBRX) Stock Is Up 5.20%
As of Thursday, July 30, ImmunityBio, Inc.’s IBRX share price has surged by 5.20%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | IBRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,266.7 | $292.6 | 74% |
|
| Shares Out (Mil) | 1,050.1 | 54.4 | 94% |
|
| Institutional Ownership | 41.3% | 93.2% | 17% |
|
| Float (Mil) | 406.6 | 40.2 | 83% |
|
| Beta | 0.13 | 0.94 | 10% |
|
| Avg Daily Volume (000s) | 6,825 | 544 | 95% |
|
| Price Change (52-week) |
245.1% | 59.7% | 98% |
|
| Growth | IBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 185.2% | 13.6% | 100% |
|
| Net Income (5yr) | (9.6%) | (10.1%) | 30% |
|
| EPS (5yr) | 8.3% | 16.0% | 44 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 11.4% | (15.6%) | 70% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($0.050) | ($0.915) | ($0.127) | |
| Month Ago EPS | ($0.070) | na | $0.060 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.065) | ($0.790) | $0.105 | |
| Year/Year Chg | (77.2%) | 139.5% | (196.9%) | |
| Financials | IBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $166 | $37 | 30% |
|
| Net Income (TTM) (Mil) | ($992) | ($43) | 2% |
|
| EPS (TTM) | ($0.989) | ($1.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($281) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($61) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $1,221 | $4 | 68% |
|
| Enterprise Value (Q1) (Mil) | $8,556 | $164 | 71% |
|
| Valuation | IBRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IBRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 99.3% | 64.2% | 96% |
|
| Net Margin | (598.6%) | (75.9%) | 1% |
|
| ROA | (192.6%) | (47.5%) | 2% |
|
| ROE | 122.7% | (55.0%) | 97% |
|
| Liabilities to Assets | 266.4% | 29.6% | 99% |
|
| F-Score | 3 | 3 | 18% |
|
ImmunityBio, Inc. did not pass any screens on 8/21/2026.
